User requirements for non-invasive and minimally invasive glucose self-monitoring devices in low-income and middle-income countries : a qualitative study in Kyrgyzstan, Mali, Peru and Tanzania
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
AIMS: Development of non-invasive and minimally invasive glucose monitoring devices (NI-MI-GMDs) generally takes place in high-income countries (HICs), with HIC's attributes guiding product characteristics. However, people living with diabetes (PLWD) in low-income and middle-income countries (LMICs) encounter different challenges to those in HICs. This study aimed to define requirements for NI-MI-GMDs in LMICs to inform a target product profile to guide development and selection of suitable devices.
METHODS: This was a multiple-methods, exploratory, qualitative study conducted in Kyrgyzstan, Mali, Peru and Tanzania. Interviews and group discussions/activities were conducted with healthcare workers (HCWs), adults living with type 1 (PLWD1) or type 2 diabetes (PLWD2), adolescents living with diabetes and caregivers.
RESULTS: Among 383 informants (90 HCW, 100 PLWD1, 92 PLWD2, 24 adolescents, 77 caregivers), a range of differing user requirements were reported, including preferences for area of glucose measurement, device attachment, data display, alert type and temperature sensitivity. Willingness to pay varied across countries; common requirements included ease of use, a range of guiding functions, the possibility to attach to a body part of choice and a cost lower than or equal to current glucose self-monitoring.
CONCLUSIONS: Ease-of-use and affordability were consistently prioritised, with broad functionality required for alarms, measurements and attachment possibilities. Perspectives of PLWD are crucial in developing a target product profile to inform characteristics of NI-MI-GMDs in LMICs. Stakeholders must consider these requirements to guide development and selection of NI-MI-GMDs at country level, so that devices are fit for purpose and encourage frequent glucose monitoring among PLWD in these settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
BMJ open - 14(2024), 2 vom: 17. Feb., Seite e076685 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Safary, Elvis [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 21.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2023-076685 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368580318 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368580318 | ||
| 003 | DE-627 | ||
| 005 | 20240222091950.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240218s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2023-076685 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1301.xml |
| 035 | |a (DE-627)NLM368580318 | ||
| 035 | |a (NLM)38367964 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Safary, Elvis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a User requirements for non-invasive and minimally invasive glucose self-monitoring devices in low-income and middle-income countries |b a qualitative study in Kyrgyzstan, Mali, Peru and Tanzania |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 21.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a AIMS: Development of non-invasive and minimally invasive glucose monitoring devices (NI-MI-GMDs) generally takes place in high-income countries (HICs), with HIC's attributes guiding product characteristics. However, people living with diabetes (PLWD) in low-income and middle-income countries (LMICs) encounter different challenges to those in HICs. This study aimed to define requirements for NI-MI-GMDs in LMICs to inform a target product profile to guide development and selection of suitable devices | ||
| 520 | |a METHODS: This was a multiple-methods, exploratory, qualitative study conducted in Kyrgyzstan, Mali, Peru and Tanzania. Interviews and group discussions/activities were conducted with healthcare workers (HCWs), adults living with type 1 (PLWD1) or type 2 diabetes (PLWD2), adolescents living with diabetes and caregivers | ||
| 520 | |a RESULTS: Among 383 informants (90 HCW, 100 PLWD1, 92 PLWD2, 24 adolescents, 77 caregivers), a range of differing user requirements were reported, including preferences for area of glucose measurement, device attachment, data display, alert type and temperature sensitivity. Willingness to pay varied across countries; common requirements included ease of use, a range of guiding functions, the possibility to attach to a body part of choice and a cost lower than or equal to current glucose self-monitoring | ||
| 520 | |a CONCLUSIONS: Ease-of-use and affordability were consistently prioritised, with broad functionality required for alarms, measurements and attachment possibilities. Perspectives of PLWD are crucial in developing a target product profile to inform characteristics of NI-MI-GMDs in LMICs. Stakeholders must consider these requirements to guide development and selection of NI-MI-GMDs at country level, so that devices are fit for purpose and encourage frequent glucose monitoring among PLWD in these settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a general diabetes | |
| 650 | 4 | |a health equity | |
| 650 | 4 | |a health services accessibility | |
| 650 | 4 | |a patient-centered care | |
| 650 | 4 | |a qualitative research | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 700 | 1 | |a Beran, David |e verfasserin |4 aut | |
| 700 | 1 | |a Vetter, Beatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Lepeska, Molly |e verfasserin |4 aut | |
| 700 | 1 | |a Abdraimova, Aida |e verfasserin |4 aut | |
| 700 | 1 | |a Dunganova, Asel |e verfasserin |4 aut | |
| 700 | 1 | |a Besançon, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Lazo-Porras, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Portocarrero Mazanett, Jill |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-León, Silvana |e verfasserin |4 aut | |
| 700 | 1 | |a Maixenchs, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Nchimbi, Happy |e verfasserin |4 aut | |
| 700 | 1 | |a Ramaiya, Kaushik |e verfasserin |4 aut | |
| 700 | 1 | |a Munishi, Castory |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Pérez, Guillermo Z |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 14(2024), 2 vom: 17. Feb., Seite e076685 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:2 |g day:17 |g month:02 |g pages:e076685 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2023-076685 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 2 |b 17 |c 02 |h e076685 | ||